 4. Patients with known active central nervous system CNS metastases andor carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable without evidence of progression by imaging for at least four weeks prior to the first dose of Study treatment and any neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases, and are not using steroids for at least 28 days prior to Study treatment. 